Rein Therapeutics
RNTX
43 hedge funds and large institutions have $33.6M invested in Rein Therapeutics in 2021 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 11 increasing their positions, 10 reducing their positions, and 9 closing their positions.
10% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 10
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0.02% less ownership
Funds ownership: 1.84% → 1.82% (-0.02%)
9% less funds holding
Funds holding: 47 → 43 (-4)
19% less capital invested
Capital invested by funds: $41.5M → $33.6M (-$7.93M)
44% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 9
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VF
Virtu Financial
New York
|
+$198K |
| 2 |
William Blair & Company
Chicago,
Illinois
|
+$126K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$61.5K |
| 4 |
JWA
JFS Wealth Advisors
Hermitage,
Pennsylvania
|
+$34.8K |
| 5 |
GPFA
Game Plan Financial Advisors
Westlake,
Ohio
|
+$29.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$325K |
| 2 |
Two Sigma Advisers
New York
|
-$156K |
| 3 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$97K |
| 4 |
BFM
Boothbay Fund Management
New York
|
-$88.4K |
| 5 |
KWM
Keebeck Wealth Management
Chicago,
Illinois
|
-$87.2K |
RNTX Hedge Fund Activity: Q3 2021 in Review
43 of the 5,713 institutional investors tracked by Wall St. Rank reported a position in Rein Therapeutics (RNTX) for Q3 2021, worth a combined $33.6M — down 19% from $41.5M a quarter earlier.
Sellers outnumbered buyers: 9 funds closed out of RNTX and 5 opened new positions — a net loss of 4 holders — while 10 trimmed existing stakes and 11 added.
The largest buyer was Virtu Financial, opening a new position worth an estimated $198K. The largest seller was Renaissance Technologies, cutting an estimated $325K.
- 43 institutional investors held Rein Therapeutics (RNTX) as of Q3 2021, down from 47 in Q2 2021.
- Funds reported $33.6M of Rein Therapeutics stock for Q3 2021, down 19% quarter-over-quarter.
- 5 funds opened new Rein Therapeutics positions in Q3 2021 and 9 closed out, a net change of -4 holders.
- The largest Rein Therapeutics buyer in Q3 2021 was Virtu Financial, an estimated $198K added.
- The largest Rein Therapeutics seller in Q3 2021 was Renaissance Technologies, an estimated $325K sold.
Based on aggregated 13F filings for Q3 2021.